Fereshteh Ashtari1, Nafiseh Toghianifar2, Sayyed Hamid Zarkesh-Esfahani3, Marjan Mansourian4. 1. a Department of Neurology , Isfahan University of Medical sciences , Isfahan , Iran. 2. b Isfahan Neuroscience Research Center , Isfahan University of Medical Sciences , Isfahan , Iran. 3. c Department of Biology , University Of Isfahan , Isfahan , Iran. 4. d Department of Biostatistics and Epidemiology, Health School , Isfahan University of Medical Sciences , Isfahan , Iran.
Abstract
BACKGROUND: Low level of vitamin D is associated with a more severe course and low quality of life in relapsing-remitting multiple sclerosis (RRMS). Low dose vitamin D intake has improved quality of life in RRMS patients. OBJECTIVE: This study explored the effect of high dose vitamin D intake on quality of life in RRMS patients in a double blind randomized clinical trial. METHODS:94 RRMS patients were randomized to two groups. One group received 50,000 IU vitamin D3 every five days for 3 months. The other group received placebo. Interferon-β (IFN-β) continued as the main treatment in both groups. Quality of life was assessed using MSQOL-54 Persian version at the beginning and at the end of the study. RESULTS: After 3 months, the vitamin D group had a significant difference in mental health composite with placebo group, 62.41 ± 13.99 vs. 60.99 ± 17.99 (p-value = 0.041). Change in health was 75.74 ± 25.73 and 70.59 ± 26.45 in vitamin D and placebo group, respectively (p-value = 0.036). CONCLUSIONS:Mental QOL improved significantly after taking high dose vitamin D for 3 months in vitamin D group relative to placebo.
RCT Entities:
BACKGROUND: Low level of vitamin D is associated with a more severe course and low quality of life in relapsing-remitting multiple sclerosis (RRMS). Low dose vitamin D intake has improved quality of life in RRMS patients. OBJECTIVE: This study explored the effect of high dose vitamin D intake on quality of life in RRMS patients in a double blind randomized clinical trial. METHODS: 94 RRMS patients were randomized to two groups. One group received 50,000 IU vitamin D3 every five days for 3 months. The other group received placebo. Interferon-β (IFN-β) continued as the main treatment in both groups. Quality of life was assessed using MSQOL-54 Persian version at the beginning and at the end of the study. RESULTS: After 3 months, the vitamin D group had a significant difference in mental health composite with placebo group, 62.41 ± 13.99 vs. 60.99 ± 17.99 (p-value = 0.041). Change in health was 75.74 ± 25.73 and 70.59 ± 26.45 in vitamin D and placebo group, respectively (p-value = 0.036). CONCLUSIONS: Mental QOL improved significantly after taking high dose vitamin D for 3 months in vitamin D group relative to placebo.
Entities:
Keywords:
Mental health; Multiple sclerosis; Physical health; Quality of life; Vitamin D
Authors: William Camu; Philippe Lehert; Charles Pierrot-Deseilligny; Patrick Hautecoeur; Anne Besserve; Anne-Sophie Jean Deleglise; Marianne Payet; Eric Thouvenot; Jean Claude Souberbielle Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-08-06
Authors: Vanitha A Jagannath; Graziella Filippini; Carlo Di Pietrantonj; G V Asokan; Edward W Robak; Liz Whamond; Sarah A Robinson Journal: Cochrane Database Syst Rev Date: 2018-09-24
Authors: A Giustina; R A Adler; N Binkley; J Bollerslev; R Bouillon; B Dawson-Hughes; P R Ebeling; D Feldman; A M Formenti; M Lazaretti-Castro; C Marcocci; R Rizzoli; C T Sempos; J P Bilezikian Journal: Rev Endocr Metab Disord Date: 2020-03 Impact factor: 6.514